ReviewInternational journal for equity in health2019
Women in clinical trials: a review of policy development and health equity in the Canadian context.
Review in International journal for equity in health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Vaginal microbiomes and their pertinent social context: a microbial ecological review proffering AMR-STI acquisition and emergence.Biology of sex differences · 2026Review
- Growing together: reflections on Canada's first interdisciplinary women's health research training program.Humanities & social sciences communications · 2026Article
- Intersectoral action to transform health equity for women and girls globally.Communications medicine · 2025Review
- Exploring the definitions of gender bias in healthcare literature: a scoping review protocol.MethodsX · 2025Article
- Exploratory Study of Sex Differences in P-Glycoprotein Function at the Blood-Brain Barrier.Clinical and translational science · 2025Article
- Use of HSALab animal · 2025Article
- Biases in machine-learning models of human single-cell data.Nature cell biology · 2025Review
- The AMerican PREGNANcy Mother-Child CohorT: description and prevalence of baseline outcomes and medication dispensing.Frontiers in pharmacology · 2025Article
- An international questionnaire highlights and supports the case for including girls in Creatine Transporter Deficiency research.Frontiers in neuroscience · 2025Article
- Treating Mycoplasma genitalium (in pregnancy): a social and reproductive justice concern.Monash bioethics review · 2024Article
- The Appropriateness of Medical Devices Is Strongly Influenced by Sex and Gender.Life (Basel, Switzerland) · 2024Review
- How the structural determinants of health inequities impact access to prescription medication for pregnant women in Australia: a narrative review.The Lancet regional health. Western Pacific · 2024Review
- Gender parity in high impact neurology journals.eNeurologicalSci · 2023Article
- Are we moving the dial? Canadian health research funding trends for women's health, 2S/LGBTQ + health, sex, or gender considerations.Biology of sex differences · 2023Article
- Uncovering Knowledge Gaps in the Safety Profile of Antiangiogenic Drugs in Cancer Patients: Insights from Spontaneous Reporting Systems Studies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Sex-divergent effects on the NAD+-dependent deacetylase sirtuin signaling across the olfactory-entorhinal-amygdaloid axis in Alzheimer's and Parkinson's diseases.Biology of sex differences · 2023Article
- Sex, Gender, and the Regulation of Prescription Drugs: Omissions and Opportunities.International journal of environmental research and public health · 2023Review
- Considerations of sex and gender dimensions by research ethics committees: a scoping review.International health · 2022Article
- An analysis of neuroscience and psychiatry papers published from 2009 and 2019 outlines opportunities for increasing discovery of sex differences.Nature communications · 2022Article
- Facilitators and barriers of women's participation in HIV clinical research in Switzerland: A qualitative study.HIV medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Health equity in pharmaceutical research is concerned with creating equal opportunities for men and women to partake in clinical trials. Equitable representation is imperative for determining the safety, effectiveness, and tolerance of drugs for all consumers. Historically, women have been excluded from participating in clinical research leading to a lack of knowledge regarding drug effects and their consequences. This paper examines the changes made since the implementation of Canadian policies on the representation of women in clinical trials, the analysis of sex and gender, as well as the discourses that are prominent among researchers. A feminist ethics framework is used to examine the structures that endeavor to elucidate women's involvement in trials, as experienced under extensive patriarchal history. Scholarly literature and Canadian government policy documents are used to explore the development of clinical trials as pertaining to sex and gender. Findings suggest that women continue to be underrepresented or excluded from important research, highlighting ongoing ethical and justice concerns. Improvement recommendations for policies are outlined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.